In the BioHarmony Drug Report Database
Moxifloxacin
Avelox, Moxeza, Moxifloxacin, Vigamox (moxifloxacin) is a small molecule pharmaceutical. Moxifloxacin was first approved as Avelox on 1999-12-10. It is used to treat bacterial infections, bacterial pneumonia, bacteroides infections, bronchitis, and cystitis amongst others in the USA. Vigamox’s patent is valid until 2029-05-29 (FDA).
Trade Name
|
Avelox, Moxeza, Moxifloxacin, Vigamox |
|---|---|
Common Name
|
moxifloxacin |
ChEMBL ID
|
CHEMBL32 |
Indication
|
bacterial infections, bacterial pneumonia, bacteroides infections, bronchitis, cystitis, escherichia coli infections, gonorrhea, haemophilus infections, klebsiella infections, proteus infections, protozoan infections, pseudomonas infections, pyelonephritis, salmonella infections, sinusitis, staphylococcal infections, streptococcal infections, urinary tract infections |
Drug Class
|
Antibacterials (quinolone derivatives) |
Image (chem structure or protein)